Chemoreflex Sensitivity in Chronic Kidney Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Cardiovascular morbidity and mortality are markedly increased in chronic kidney disease (CKD) and may be explained in part by sympathetic hyperactivity. Impaired hyperoxic chemoreflex sensitivity (CHRS) has been attributed to an increased sympathetic activity. The aim of the present study is to examine whether chemosensor function is altered in patients with stage 3 and stage 4 CKD.
| Condition | Intervention |
|---|---|
|
Chronic Kidney Disease Cardiovascular Morbidity |
Other: blood sampling |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Hyperoxic Chemoreflex Sensitivity in Chronic Kidney Disease |
- Hyperoxic chemoreflex sensitivity is impaired in patients with moderate to severe chronic kidney disease [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Measurement of the venous partial pressure of oxygen in blood samples
| Enrollment: | 65 |
| Study Start Date: | January 2007 |
| Study Completion Date: | November 2008 |
| Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
Patients with stage 3 CKD
|
Other: blood sampling |
|
2
Patients with stage 4 CKD
|
Other: blood sampling |
|
3
Patients without evidence for CDK
|
Other: blood sampling |
Detailed Description:
Impaired hyperoxic chemoreflex sensitivity (CHRS) is assessed in patients with stage 3 CKD [glomerular filtration rate (GFR) 30-59 ml/min/1.73 m2], in patients with stage 4 CKD [GFR 15-29 ml/min/1.73 m2], as well as in patients without any evidence of CKD. CHRS is measured by determination of the venous partial pressure of oxygen and the heart rate before and after deactivation of the chemoreceptors by inhalation of pure oxygen. The difference in the R-R intervals before and after inhalation divided by the difference in the oxygen pressures is calculated as the CHRS. A CHRS below 3.0 ms/mmHg is defined as pathological. It should be shown that using a simple clinical bedside test we provide the first evidence for impaired hyperoxic chemoreflex sensitivity in stage 3 and 4 chronic kidney disease. We thereby may lay the basis for future intervention studies assessing chemosensor function in these patients.
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients suffering from CDK stage 3 (GFR 30-59 ml/min/1.73 m²) or stage 4 (GFR 15-29 ml/min/1.73 m²)
- For the reference Patients without evidence for CDK
Exclusion Criteria:
- Patients with heart failure, history of myocardial infarction or instable angina pectoris, atrial fibrillation, hyperthyroidism, chronic pulmonary diseases, sleep apnoea syndrome, alcohol abuse and drug induced cardiomyopathy
Contacts and Locations| Germany | |
| Department of Medicine, Division of Cardiology, Pulmonology and Vascular Medicine | |
| Aachen, NRW, Germany, 52074 | |
| Principal Investigator: | Christian Meyer, MD | RWTH Aachen University Departement of Cardiology, Pulmonology and Vascular Medicine |
More Information
No publications provided
| Responsible Party: | Christian Meyer, MD, RWTH Aachen University |
| ClinicalTrials.gov Identifier: | NCT00794872 History of Changes |
| Other Study ID Numbers: | Chemoreflex-Sensitivity-Study |
| Study First Received: | November 19, 2008 |
| Last Updated: | November 19, 2008 |
| Health Authority: | Germany: Ethics Committee |
Keywords provided by RWTH Aachen University:
|
Cardiovascular autonomic neuropathy Chemoreflex sensitivity Chronic kidney disease Sudden cardiac arrest |
Additional relevant MeSH terms:
|
Kidney Diseases Renal Insufficiency, Chronic Kidney Failure, Chronic Urologic Diseases Renal Insufficiency |
ClinicalTrials.gov processed this record on May 19, 2013